Literature DB >> 15637392

Cancer screening in theory and in practice.

Otis W Brawley1, Barnett S Kramer.   

Abstract

Improvements in technology have led to a number of tests that can be used to suggest that a patient has a cancer. Advances in cancer biology and medical imaging have led to a number of cancer screening tests. Cancer screening is commonly advocated, but its complexity is often lost in guidelines that have sound-bite quality. It is commonly viewed as of no harm, when in fact there are harms associated with every known screening test. Indeed, many screening experts believe a screening test should only be used when the potential for benefit clearly outweighs the potential for harm. Cancer screening principles are classically within the realm of the epidemiologist. As more screening tests are developed, these principles have become more relevant to the practicing clinician. What is known and what is unknown about screening is distinctly different from what is believed by the public and many practicing clinicians. Many tests have both screening and diagnostic uses, and it is only the context in which these are used that determines whether they are screening or diagnostic. A screening test is done on asymptomatic individuals who receive the test principally because they are of the age or sex at risk for the cancer. A diagnostic test is done on an individual because of clinical suspicion of disease.

Entities:  

Mesh:

Year:  2005        PMID: 15637392     DOI: 10.1200/JCO.2005.06.107

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  21 in total

Review 1.  Contemporary progress in ovarian cancer screening.

Authors:  Christine S Walsh; B Y Karlan
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

Review 2.  Molecular signatures of ovarian cancer: from detection to prognosis.

Authors:  Christine S Walsh; Beth Y Karlan
Journal:  Mol Diagn Ther       Date:  2010-02-01       Impact factor: 4.074

3.  Colonoscopy and colorectal cancer mortality: both sides of the story.

Authors:  Alfred I Neugut; Benjamin Lebwohl
Journal:  Therap Adv Gastroenterol       Date:  2013-05       Impact factor: 4.409

4.  The effect of expert knowledge on medical search: medical experts have specialized abilities for detecting serious lesions.

Authors:  Ryoichi Nakashima; Chisaki Watanabe; Eriko Maeda; Takeharu Yoshikawa; Izuru Matsuda; Soichiro Miki; Kazuhiko Yokosawa
Journal:  Psychol Res       Date:  2014-10-01

5.  A qualitative analysis of lung cancer screening practices by primary care physicians.

Authors:  Susan Henderson; Amy DeGroff; Thomas B Richards; Julia Kish-Doto; Cindy Soloe; Christina Heminger; Elizabeth Rohan
Journal:  J Community Health       Date:  2011-12

6.  Prevalence of abnormalities influences cytologists' error rates in screening for cervical cancer.

Authors:  Karla K Evans; Rosemary H Tambouret; Andrew Evered; David C Wilbur; Jeremy M Wolfe
Journal:  Arch Pathol Lab Med       Date:  2011-12       Impact factor: 5.534

7.  The development of a web- and a print-based decision aid for prostate cancer screening.

Authors:  Caroline S Dorfman; Randi M Williams; Elisabeth C Kassan; Sara N Red; David L Dawson; William Tuong; Elizabeth R Parker; Janet Ohene-Frempong; Kimberly M Davis; Alexander H Krist; Steven H Woolf; Marc D Schwartz; Mary B Fishman; Carmella Cole; Kathryn L Taylor
Journal:  BMC Med Inform Decis Mak       Date:  2010-03-03       Impact factor: 2.796

8.  Beliefs Regarding Prostate Cancer Screening Among Black Males Aged 18 to 40 Years.

Authors:  Motolani E Ogunsanya; Carolyn M Brown; Folakemi T Odedina; Jamie C Barner; Brittany Corbell; Taiwo B Adedipe
Journal:  Am J Mens Health       Date:  2016-07-08

Review 9.  Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.

Authors:  M Mimeault; S K Batra
Journal:  Panminerva Med       Date:  2008-03       Impact factor: 5.197

Review 10.  Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies.

Authors:  M Mimeault; R Hauke; S K Batra
Journal:  Clin Pharmacol Ther       Date:  2007-09-05       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.